NR2E1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-4: Human cerebrum tissue, A172 cell, Mouse brain tissue, NIH/3T3 cell lysates, Primary antibody: P10424(NR2E1 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P10424(NR2E1 Antibody) at dilution 1/160. (Original magnification: ×200)    

  
  

NR2E1 (Nuclear Receptor Subfamily 2 Group E Member 1), also known as TLX, is a ligand-dependent transcription factor belonging to the nuclear receptor superfamily. It plays a critical role in regulating gene expression during neural development, stem cell maintenance, and retinal homeostasis. Structurally, NR2E1 contains a DNA-binding domain (DBD) and a ligand-binding domain (LBD), enabling it to interact with specific DNA sequences and modulate target gene activity. It is highly expressed in the brain, particularly in neural stem cells, and the retina, where it influences cell proliferation, differentiation, and apoptosis. Dysregulation of NR2E1 has been linked to neurological disorders, psychiatric conditions, and retinal degenerative diseases, as well as tumorigenesis in glioblastoma and other cancers.

NR2E1 antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP) to investigate NR2E1's role in neural development, cancer biology, and retinal diseases. Researchers often validate antibody specificity using knockout controls or siRNA-mediated knockdown. Commercial NR2E1 antibodies are available from multiple suppliers, targeting distinct epitopes (e.g., N-terminal or C-terminal regions). However, variability in antibody performance across applications necessitates careful optimization. Recent studies also explore NR2E1's potential as a therapeutic target, further driving demand for reliable antibodies in preclinical research.